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G protein-coupled receptors (GPCRs) are membrane receptors critically involved in 
sensing the environment and orchestrating physiological processes. As such, they 
transduce extracellular signals such as hormone, neurotransmitters, ions, and light into 
an integrated cell response. The intracellular trafficking, internalization, and signaling 
ability of ligand-activated GPCRs are controlled by arrestins, adaptor proteins that they 
interact with upon ligand binding. β-arrestins 1 and 2 in particular are now considered as 
hub proteins assembling multiprotein complexes to regulate receptor fate and transduce 
diversified cell responses. While more than 400 β-arrestin interaction partners have 
been identified so far, much remains to be learnt on how discrimination between so 
many binding partners is accomplished. Here, we gathered the interacting partners of 
β-arrestins through database mining and manual curation of the literature to map the 
β-arrestin interactome (β-arrestinome). We discussed several parameters that determine 
compatible (AND) or mutually exclusive (XOR) binding of β-arrestin interactors, such as 
structural constraints, intracellular abundance, or binding affinity.
Keywords: hub proteins, β-arrestins, G protein-coupled receptors, protein/protein interaction network, systems 
biology
introdUCtion
G protein-coupled receptors (GPCRs) are the largest class of integral membrane receptors involved 
in signal transduction from the cell environment inward. Their cognate ligands encompass a vast 
array of structural entities, including glycoprotein hormones, chemokines, peptide neurotransmit-
ters, ions, as well as sensory molecules such as light, odorants, or taste ligands. Given this plethora 
of ligands, GPCRs are involved in many physiological and pathological processes, making them 
prime target classes for drug discovery. As major transducers of GPCR activation, β-arrestins 1 and 
2 (aka arrestins 2 and 3) represent a particular subtype of hubs, their conformation and activation 
being dependent upon their association to ligand-bound receptor. β-arrestins contribute to connect 
the extracellular milieu to the intracellular space, by desensitizing and internalizing the receptor 
in order to avoid endless second messenger production at the plasma membrane, and by scaffold-
ing signaling modules that can be activated independently, or in conjunction with G proteins. A 
key factor in determining β-arrestin binding specificity is their sensitivity to the phosphorylation 
taBLe 1 | number of β-arrestins 1 and 2 partners retrieved from manual 
curation of the literature and by queries in publicly available databases.
Querya β-arrestin 1 β-arrestin 2
Xiao et al. (13) 158 244
NetPath 21 27
BioGRID 40 27
Mentha 10 7
HIPPIE 4 30
Manual curation 49 39
Total 282 374
aIn each subsequent source, the additional interactions found with respect to the 
previous one were sequentially added.
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barcode of the receptor, which dictates the affinity of the interac-
tion and the conformation they adopt (1, 2). In particular, some 
agonist-stimulated GPCRs are phosphorylated on distinct sites 
by G protein-coupled receptor kinases (GRK) 5 or 6, and by 
GRK2 or 3 (3–7). These combinatorial phosphorylations impart 
variable conformations of the β-arrestins recruited at the GPCR 
carboxy terminus. Consequently, β-arrestins recruited on the 
receptor at GRK5 and 6 phosphorylated sites lead to the assembly 
of a signalosome, such as the ERK MAP kinase module, while 
β-arrestins recruited at GRK2 and 3 phosphosites promote recep-
tor internalization (1, 2, 7–10). In addition, β-arrestins binding at 
the GPCR carboxy terminus can co-exist with G protein binding 
in endosomes, which sustains G protein signaling inside the cell 
(11). Finally, some interactors also bind free β-arrestins, such as 
microtubules, calmodulin, and the E3 ubiquitin ligases MDM2 
and Parkin (12) among others, extending the role of β-arrestins 
to GPCR-independent signaling.
Although more than 400 of their protein partners have been 
identified (13), the relatively small size (45 kDa) of β-arrestins 
and their limited potential interaction interface, estimated as 
17,000 Å2, precludes their interaction with as many interacting 
partners at a time. By analogy with Boolean logic gate opera-
tors of electronic circuits, compatible surface interactions can 
be distinguished from mutually exclusive interactions with 
the “AND” and “XOR” operators, respectively (14–16). A 
prominent cause of XOR interactions relies on structural 
constraints imposed by the availability of β-arrestin docking 
sites, as illustrated by the interaction between β-arrestin 2 and 
tubulin, Ca2+-dependent calmodulin, and GPCR, which all use 
the same binding site (17). Protein abundances together with 
affinities may also invoke competition between binding part-
ners for a common docking site on β-arrestins and ultimately 
contribute to cell- and tissue-specific signaling responses. 
Here, we gathered the current knowledge on interaction 
partners for β-arrestins 1 and 2 (encoded by the ARRB1 and 
ARRB2 genes, respectively) to provide a comprehensive map 
of the “β-arrestinome.”
tHe β-arrestinoMe
In order to retrieve β-arrestin protein partners and reconstruct 
a comprehensive β-arrestin interaction map, we searched for 
β-arrestin-binding partners in the literature and in publicly avail-
able protein interaction databases. First, most of the interactions 
were extracted from a previously published proteomics analysis 
of the β-arrestin interactome, following coimmunoprecipitation 
of FLAG-tagged β-arrestins 1 and 2 in HEK293 cells stimulated 
by angiotensin II, and peptide identification by mass spectrom-
etry (MS) (MudPIT and LC–MS/MS) (13). Then, some more 
β-arrestin partners were sequentially retrieved from queries in 
NetPath (release 9) (18), BioGRID (3.4 version) (19), Mentha (25-
09-2016 release) (20), and HIPPIE (v2.0 24-06-2016) (21) data-
bases. All the relevant experiments were verified in the original 
publications. Finally, the analysis was completed by manual cura-
tion of the literature. All this information was used to build the 
β-arrestin interactome. To get all interactions between β-arrestin 
partners, the interaction networks were inferred in HIPPIE (21) 
that automatically converts protein–protein interactions into a 
connected network.
Upon public database queries and manual curation of the 
literature, 282 experimentally validated interactions were 
recovered for β-arrestin 1 and 374 for β-arrestin 2 (Table 1). The 
whole β-arrestinome and interactions among partners, visualized 
using Cytoscape (22), comprises 429 unique nodes and 1,599 
unique edges (Figure  1A). We discriminated direct (yellow 
diamonds) and indirect interactions. Direct interactions have 
been revealed by yeast two-hybrid or by in  vitro-reconstituted 
complex of purified recombinant proteins (called “direct” in 
Table S1 in Supplementary Material). Interactions uncovered 
in the same macromolecular complexes by immunoprecipita-
tion or pull down assays (called “undetermined” in Table S1 in 
Supplementary Material) could be direct or not. From this view, 
the partners common to both β-arrestins (highlighted in red) are 
involved in some of β-arrestin key biological functions, such as 
intracellular trafficking (SRC, MDM2, and CAV1), cell signaling 
(MAPK pathways, 14-3-3 proteins, SRC, AKT1, and CALM1), 
gene transcription (PRMT5, NPM1, and POLR2E), or cytoskel-
eton remodeling (CDC42, LIMK1, FLNA, RALGDS, and CFL1). 
Others are involved in RNA processing, protein biosynthesis, and 
chromatin remodeling. The data that impose the heaviest weight 
on our whole analysis mainly rely on a single study using a com-
mon anti-FLAG antibody to immunoprecipitate both β-arrestins, 
prior to two distinct state-of-the-art MS analyses (13), which 
likely limits random under-representation of the partners of one 
or the other β-arrestin.
It is conceivable that hub proteins, such as TP53, MDM2, 
SUMO1, and 14-3-3 proteins support many indirect interac-
tions between β-arrestins and their partners. In addition, since 
β-arrestins could heterodimerize (23), any of the two β-arrestins 
could indirectly connect the other one with its own binding 
proteins.
In light of the present knowledge, about 17.2% of all the 
reported partners of both β-arrestins, not including the recep-
tors, have been experimentally validated as direct binders [57 
(22.7% of the direct interactors) for β-arrestin 1 and 44 (13.1%) 
for β-arrestin 2, the remaining ones binding to both β-arrestins] 
(Table S1 in Supplementary Material). In total, 26 interactions 
demonstrated as direct ones are common to both β-arrestins, rep-
resenting 25.7% of the direct ones and 4.4% of the total. Besides 
these experimentally validated direct interactions, the question 
AB
FiGUre 1 | Continued
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FiGUre 1 | Continued 
(a) β-Arrestins 1 and 2 interactome, represented as a non-directional interaction graph in Cytoscape, according to Table S1 in Supplementary Material. Each node 
represents a protein, whereas each edge represents an interaction, as reconstituted with the HIPPIE algorithm to visualize not only interactions with β-arrestins but 
also interactions among β-arrestin partners. Interactions experimentally shown for one or the other β-arrestin selectively are in gray for β-arrestin 1 and blue for 
β-arrestin 2, whereas the interactions demonstrated for both are in red. β-arrestins are in turquoise. Yellow diamonds indicate partners interacting directly at least 
with one β-arrestin. The size of each node is proportional to its degree of connectivity. (B) Projection of the first neighbors (n + 1, green) of the experimentally 
validated direct interaction partners of β-arrestins (n, vermilion) on the whole β-arrestinome, as determined by IPA. The direct interaction partners for which no first 
neighbors have been identified within the β-arrestinome are in light pink. The proteins have been sorted according to their biological function. For simplification 
purpose, the receptor class has been omitted. Symbols indicated are the Uniprot gene names (http://www.uniprot.org).
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remains open as to whether the other interactions in the whole 
β-arrestinome also include direct ones.
Considering a subnetwork composed of β-arrestin direct inter-
actors denoted as n, we artificially extended it with the respective 
first neighbors of these nodes (n + 1). Then, these n + 1 nodes 
were projected on the whole β-arrestinome (Figure 1B). By these 
means, 112 (33%) of nodes coincided with these n + 1 interac-
tions, when no filter was applied on the type of interaction, i.e., 
both functional and physical interactions were considered. When 
considering only protein–protein interactions, this ratio still 
reaches 21% (24% when adding phosphorylation relationships 
and 25% when considering ubiquitination). Since n +  1 nodes 
are in close contact with β-arrestin direct binders, these nodes 
have to be considered as putative direct interactors of β-arrestins 
also. For example, PTEN has previously been shown to activate 
the actin depolymerization factor cofilin (24), and we propose 
that β-arrestins could scaffold this complex, although cofilin has 
not been shown as a β-arrestin direct binder yet. This possibility 
deserves to be experimentally addressed in the future.
strUCtUraL MappinG oF β-arrestin 
direCt interaCtors
It was proposed earlier that extensive conformational flexibility 
of β-arrestins allows them to adopt many different interfaces, 
which may provide an explanation for why their relatively small 
surface can accommodate so many different binding partners. 
In an attempt to support this view, we used PepX, an algorithm 
that has been demonstrated earlier to predict docking sites with 
high precision based on a library of peptide–peptide interac-
tions (25). Using different β-arrestin protein structures as the 
input (PDB entries 2WTR, 4JQI, and 3P2D), PepX was used 
to determine the accessible conformational space for possible 
bound peptide backbone fragments through interaction con-
straints using them as anchors. The algorithm is based on the 
finding that protein–peptide binding occurs for a certain limited 
number of conformations. Thus, a heuristic algorithm (CSP) is 
applied in order to reduce the conformational search space of all 
overlapping fragments of the PepX database (containing more 
than 7 × 106 interactions from 1,431 PDB structures representing 
the structural coverage of protein–peptide interactions). This is 
followed by an unsupervised clustering method to predict pos-
sible binding sites and peptide conformations. In the first step, 
this algorithm predicts all compatible backbone conformations 
(“fitting”). In the second and more time-consuming step, the 
interface can be refined by taking side chain modeling into 
account (“binding”).
Using three template structures, namely, dimeric bovine 
β-arrestin 1 (unpublished), active rat β-arrestin 1 bound to a V2 
receptor phosphopeptide (1), and bovine β-arrestin 2 (26), we 
independently predicted the compatible backbone conforma-
tions using different peptide lengths (lengths 5, 6, 7, 8, and 9). 
With peptide length 5, several regions of β-arrestin surface were 
covered, which were proposed experimentally as docking sites 
(Figure 2; Table S2 in Supplementary Material). Most peptides 
were predicted to bind to overlapping sites on both β-arrestins 
1 (orange) and 2 (green). In contrast, in several instances, the 
peptide clouds on active (blue) versus inactive (orange) β-arrestin 
1 did not entirely match. For example, as viewed on the front 
side view, several peptides appeared to bind to active β-arrestin 
1 in a region located in the vicinity of L33 where it interacts 
with PDE4D or GNAS (yellow star) (Table S2 in Supplementary 
Material), whereas a distinct peptide cloud was predicted to inter-
act with inactive β-arrestin 1, in the region where RAF1 interacts 
(yellow arrow).
The larger the surface that was covered by peptides with 
compatible backbone conformations, the more template struc-
tures were used. This supports the idea that, depending on the 
activation state of β-arrestins, even small structural changes, 
as observed in different X-ray structures, can provide different 
interfaces for potential β-arrestin interacting partners.
Xor/and interaCtions in tHe  
β-arrestinoMe in LiGHt oF 
eXpression LeVeLs and aFFinities
Common XOR docking sites on β-arrestins do not necessarily 
lead to competition for binding among interaction partners. 
Clearly, the relative abundance of the common hub (here 
β-arrestin) and the partners are important to consider, because 
they govern the equilibrium of complex formation within the 
cell. To analyze how protein expression levels relate between 
β-arrestin partners, quantitative information for β-arrestins 1 
and 2 and 82 direct interactors including receptors was retrieved 
from RNAseq datasets of gene expression levels in 11 human 
normal tissues (http://www.medicalgenomics.org/) (Table S3 in 
Supplementary Material). The relative expression levels of direct 
β-arrestin partners were represented with the continuous map-
ping representation of Cytoscape. β-arrestin 1 mRNA appeared 
less abundant than β-arrestin 2 mRNA, although analysis of the 
FiGUre 2 | pepX docking predictions with peptide length 5 has been done on three template structures, but only the surface representation of 
β-arrestin 2 (pdB entry 3p2d) is shown here, in gray. Peptides are colored according to the template structure that was used for PepX predictions: β-arrestin 1 
(PDB entry 2WTR) in orange, β-arrestin 2 (PDB entry 3PD2) in blue, and β-arrestin 1 in active conformation (PDB entry 4JQI) in green. The yellow star shows the 
PDE4D- and GNAS-binding site; the yellow arrow points to the RAF1-binding site.
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respective protein levels shows the opposite (14, 27), suggesting 
posttranscriptional mechanisms to enhance β-arrestin 1 intracel-
lular protein level. Importantly, the cumulated amount of all 80 
direct interaction partners greatly over-exceeds the abundance 
of the two β-arrestins. This suggests that in those cases where 
interaction partners bind to a common docking site, competition 
between partners will exist. In this case, the relative abundance of 
each partner may be decisive (Figure 3; Table S3 in Supplementary 
Material). As represented with the Cytoscape software (22), both 
NFKBIA and MDM2 interact with the N terminus of β-arrestins 
(1–60), and their relative expression level in human tissues sug-
gests that the binding equilibrium might be displaced in favor 
of MDM2 in kidney and testes, whereas NFKBIA is much more 
abundant in other tissues, except in adipose tissue and heart where 
both genes are equally expressed. Likewise, GNAS, MAP2K1, and 
MAP3K5 are predicted to compete for the same docking site on 
β-arrestins on amino acids in the vicinity of the β-arrestin polar 
core, and their respective expression level varies among tissues, 
e.g., in kidney and in ovary.
Differences in the affinity of several proteins suspected to 
compete for identical docking site on β-arrestins may also affect 
apparent competitive interactions. For example, tubulin and 
calmodulin bind β-arrestins with a KD in the micromolar range, 
to be compared with the interaction with activated GPCR, which 
is in the nanomolar range (17). Given the affinity constant of the 
respective proteins, the receptor would win the race in a context 
of limiting quantities of β-arrestins. Such conditions are encoun-
tered for class A GPCR that interact transiently with β-arrestin 2, 
for which the affinity for β-arrestin 2 is thought to be higher than 
for β-arrestin 1, and that are recycled back to the plasma mem-
brane shortly after internalization (28). As mentioned above, at 
the protein level, β-arrestin 2 is generally expressed at much lower 
level than β-arrestin 1 in tissues; hence, this imbalance may have 
profound consequences on the duration of GPCR intracellular 
trafficking. However, variations in the concentration of the vari-
ous proteins are expected to compensate for differential affinities, 
following the law-of-mass action.
We generated a simple mathematical model that includes 
binding affinities and average endogenous cellular concentra-
tions, where tubulin, the GPCR, and calmodulin compete for 
binding to β-arrestins. The affinity (KD) for β-arrestin 1 with 
tubulin was assumed to be 50 μM, the affinity of β-arrestins with 
a GPCR as 10 nM, and the affinity of β-arrestin 1 with calmodulin 
as 7 μM (29). To translate affinities into kon and koff values, we 
used similar kon values (106  M−1  s−1) and calculated koff from 
the relation, KD = koff/kon. The volume of a mammalian cell was 
assumed to be 2.34 × 10−15 L (source: HeLa cells in Bionumbers). 
Endogenous tubulin concentration was estimated as 4 × 10−4 M 
(30), and endogenous calmodulin concentration as 8 × 10−9 M 
(27). Concentrations of β-arrestin and GPCR were estimated 
as 8 × 10−8 M (27). The equilibrium binding model was gener-
ated using the Intrinsic Noise Analyzer simulation software 
FiGUre 3 | Continued
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FiGUre 4 | equilibrium binding model of β-arrestin interacting with tubulin, G protein-coupled receptor (GpCr), and calmodulin. The equilibrium 
complex concentrations are depicted in the bar diagram.
FiGUre 3 | Continued 
Comparison of the mrna expression level of 13 direct binding partners of β-arrestins 1 and 2 in 11 human tissues, as indicated, according to table 
s3 in supplementary Material. XOR interactions are boxed, according to the docking site identified experimentally (see Table S2 in Supplementary Material).
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(31), followed by a time-course analysis until equilibrium. With 
this model, we found that approximately half of the available 
β-arrestins was bound to tubulin (Figure  4). As tubulin is so 
highly expressed in cells, an interesting consideration is whether 
binding of tubulin is specific or just results from the fact that it has 
a poly-Glu C-terminal tail, which may mimic the phosphorylated 
GPCR.
Yet another possibility is that the receptors, calmodulin and 
tubulin, interact with different subpopulations of β-arrestins, 
with different biological outcomes. For example, the ERK MAP 
kinase module that is able to interact with β-arrestins at the GPCR 
can also be sequestered by β-arrestins on the microtubules, which 
blunts ERK activity (32).
Noteworthy, the conformation of β-arrestins themselves, 
depending on their binding to the receptor, is also a factor that 
crucially affects the affinity for additional interactions, as recently 
demonstrated for β-arrestin 1 binding to clathrin (2, 33, 34).
tWo eXaMpLes oF MeCHanistiC Maps 
WitHin tHe β-arrestinoMe
In an attempt to provide more mechanistic insight onto the 
integration of these numerous protein–protein interactions 
with β-arrestins, a molecular interaction map was inferred and 
represented in standardized graphical format, using the Cell 
Designer interface (35), version 4.4. This map recapitulates the 
relationships between β-arrestins and their binding partners in 
two physiological responses in which β-arrestins are involved. 
That is, β-arrestins exquisitely fine-tune the balance between pro- 
and anti-apoptotic signals in different cell types in general and 
FiGUre 5 | Mechanistic map of β-arrestin dependence of two intertwined functional cell responses, apoptosis, and immune response. Biochemical 
reactions were edited in the Cell Designer format (see included legend). The molecular species not included in the β-arrestinome are in white, membrane receptors 
are in yellow, β-arrestins 1 or 2, and both β-arrestins are colored as above. Both cell responses connect at the level of the NFKB pathway (data not shown).
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in the immune system in particular. These mechanisms exhibit 
prominent physiological relevance, and their disturbance causes 
severe pathologies, such as autoimmunity or septic shock. The 
signal demonstration for the physiological role of arrestins in 
cell death/survival was that visual arrestin impairment acceler-
ates retinal degeneration (36). At the molecular level (Figure 5), 
β-arrestins inhibit NFKB anti-apoptotic activity by stabilizing 
the NFKBIA inhibitor. How this is achieved is not entirely clear 
because, although β-arrestins scaffold the inhibitory upstream 
kinases of NFKBIA, such as CHUK or IKBK, together with 
NFKB and NFKBIA (37), they do not seem to alter IKBK 
enzymatic activity (38). Notably, β-arrestin-mediated NFKB 
inhibition is sensitive to agonist binding on the muscarinic M1, 
AT2R (37), or β2-AR receptors (38). For example, by preventing 
β-arrestin 2 phosphorylation on S361 and S383 by casein kinase 
2, isoproterenol stimulation counteracts the anti-apoptotic role 
of NFKB in cells exposed to UV irradiation (39). GPCR activa-
tion may also lead to the formation of a receptor/β-arrestin 2/
MDM2 complex, with two major consequences: first, β-arrestin 
ubiquitination by MDM2 enhances receptor internalization (40); 
second, the interaction between β-arrestin and MDM2 pumps 
the latter out of the nucleus, which limits TP53 degradation and 
promotes its pro-apoptotic function (41). Regulation of the avail-
ability of β-arrestins themselves conditions the outcome on cell 
survival, as shown with Cx43-mediated β-arrestin sequestration 
in osteoblasts (42). More directly, caspase also triggers β-arrestins 
to interact with mitochondrial executioners of apoptosis, such as 
t-BID (43). However, β-arrestin anti-apoptotic functions have 
also been demonstrated in oxidative stress conditions, by trig-
gering MAP3K5 (ASK1) proteosomal degradation (44), or by 
counteracting FPR, V2R, CXCR2, or AT1R pro-apoptotic action 
on mitochondrial caspases (45).
Apoptosis is a programmed process that shapes the develop-
ment as well as homeostasis of the immune system. β-Arrestins 
intervene in both adaptive and innate immunity (Figure 5). As 
shown in mouse models, β-arrestin 2 stimulates the activity of 
receptors that negatively regulate NK cell cytotoxicity, such as the 
KIR2DL1 receptor (46) or dampens the activity of pro-inflam-
matory receptors, again by preventing NFKBIA degradation 
and NFKB-induced cytokine gene expression, via interaction 
with TRAF6 (47). Likewise, ligand binding to GPCR, such as 
isoproterenol-stimulated β2-AR, may lead to anti-inflammatory 
outcomes (38). In addition, β-arrestins also positively regulate 
innate immunity, as shown in  vitro by their ability to support 
the degranulation of polymorphonuclear neutrophils, through 
complexation with Src-related tyrosine kinases (48). In the 
specific context of inflammation, both β-arrestins seem to play 
opposite roles, with β-arrestin 1 favoring the oligomerization of 
NLRP3 and NLRC4 inflammasomes, in bone marrow-derived 
macrophages (49), whereas in these cells, β-arrestin 2 is involved 
in the DHA-mediated inhibition of the NLRP3 or NLRP1 
inflammasomes through GPR120 and GPR40, two receptors of 
long-chain fatty acids (50).
Homeostasis of CD4+ Lc, the cellular support of adaptive 
immunity, is also regulated in part by β-arrestin 1 that favors 
their survival by enhancing BCL2 expression level in these cells, 
through epigenetic modifications of H4 histone (51). The fact 
that ARRB1 knockout mice were much more resistant to experi-
mentally induced autoimmune encephalomyelitis highlights a 
protective role against apoptosis, in CD4+ TLc.
ConCLUdinG reMarKs
Here, we propose a snapshot of what β-arrestin signaling net-
works could look like. However, how β-arrestins orchestrate 
GPCR-dependent as well as GPCR-independent signaling is 
rather related to a movie, with simultaneous molecular events 
occurring in different places, and changing over time. Hence, 
decisive advance in understanding β-arrestin cellular functions 
requires elaborating dynamic models taking into account the 
affinities of competitors in XOR interactions, protein relative 
abundance in tissues, and subcellular distribution of the respec-
tive complexes, with, on top of that, β-arrestin dimerization 
adding even more complexity. Although not trivial to measure 
routinely, as more and more KD of interaction between signaling 
proteins become available, the dynamics of complex formation 
within the β-arrestinome will be understood more accurately.
A dynamic view of β-arrestin-dependent signaling networks 
may lead to more practical advances, because GPCR are the top 
class drug targets. β-arrestins are being intensively scrutinized 
in this respect because they transduce beneficial or detrimental 
effects; hence, biased agonists and modulators that select parts 
of a GPCR-induced signaling repertoire are being ardently 
sought after (52). As testified by the intricacy and complexity 
of the signaling networks that they regulate, it is of great inter-
est to disrupt some but not all of their interactions. To confirm 
predicted steric hindrance, co-crystals of β-arrestins with their 
direct interaction partners need to be provided, although this 
is technically and scientifically challenging. In addition, many 
works in the recent past have attempted, and partly succeeded, 
in discriminating the regulatory mechanisms that govern 
β-arrestin-mediated desensitization versus signaling. Future 
experiments will hopefully permit discrimination between the 
GPCR-dependent signaling regulatory function of β-arrestins 
and their GPCR-independent contribution to cellular compart-
mentalization. By the same token, new therapeutic agents could 
be able to disrupt a particular β-arrestin interaction in one site of 
the cell but preserve its integrity in another place. Attaining this 
Rosetta stone would pave the way for the design of drugs that 
interfere with selective interactions among spatially restricted 
β-arrestin subpopulations.
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